Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05346588 · ClinicalTrials.gov registry record · Phase 3

THRIVE Feasibility Trial

A Phase 3 study, sponsored by Washington University School of Medicine.

Completed
Registry status
Phase 3
Development phase
300
Enrollment target

NCT05346588: Completed Phase 3 study, sponsored by Washington University School of Medicine.

NCT05346588 is a Phase 3 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 300 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05346588, a Phase 3 study, has completed, sponsored by Washington University School of Medicine.

COMPLETED
Registry status
Phase 3
Development phase
300 participants
Enrollment target

Study Summary

To evaluate the feasibility of a pragmatic, large scale, comparative effectiveness, randomized evaluation of patient experience of intravenous propofol versus inhaled volatile anesthesia.

Primary Outcome

Proportion of patients who are approached to participate by the study team and who consent to participate in the study.

Interventions

  • OTHER Anesthetic technique Propofol TIVA
  • OTHER Anesthetic technique inhaled agent

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2022-09-29
Est. Completion 2023-06-28
Phase Phase 3

What the finished NCT05346588 record still lists

NCT05346588 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower).

The record links to 0 conditions, and to 2 interventions - of which Anesthetic technique Propofol TIVA is the first listed.

NCT05346588 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05346588 about?

NCT05346588 is a clinical study titled "THRIVE Feasibility Trial". To evaluate the feasibility of a pragmatic, large scale, comparative effectiveness, randomized evaluation of patient experience of intravenous propofol versus inhaled volatile anesthesia.

What is the current status of trial NCT05346588?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2022-09-29. Estimated completion is 2023-06-28.

What interventions are being tested in trial NCT05346588?

The interventions under investigation include: Anesthetic technique Propofol TIVA (OTHER), Anesthetic technique inhaled agent (OTHER).

Who is sponsoring clinical trial NCT05346588?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05346588's enrollment target sits among peer trials

300 1122nd of 2000 higher than 840 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05346588, the US trial registry maintained by the National Library of Medicine. NCT05346588 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.